Danone Q1 sales growth slowed by Middle East conflict and baby formula recall

Danone reported Q1 sales of €6.71 billion, with like-for-like growth of 2.7% driven by 1.5% volume/mix and 1.2% price increases, while the reported figure fell 2% due to a 5.6% currency headwind. Asia Pacific was the strongest region at +6% like-for-like, but Europe, Middle East and Africa slowed to +0.6% amid an infant formula recall and Middle East conflict. The company reaffirmed full-year guidance for 3%-5% like-for-like sales growth and said recurring operating income should grow faster than sales.

Analysis

The key signal is not the modest top-line beat; it’s the divergence in volume quality. Asia and North America are doing the heavy lifting while EMEA is becoming a drag from two non-recurring shocks, which means the market should start treating the region mix as a portfolio optimization problem rather than a simple demand story. If the current gap persists for two more quarters, the operating leverage benefit from Asia can be partly offset by weaker mix and higher remediation costs in Europe, especially if recalls force broader trade de-stocking.

FX is the underappreciated earnings swing factor here. A weaker USD/EM currency basket creates a mechanical translation headwind for a euro reporter, but the more important second-order effect is that it can compress local affordability and force competitors to choose between defending share and protecting margin; that usually benefits the strongest branded players with the best route-to-market. The bond issuance also matters: it telegraphs management’s willingness to lock in funding before volatility returns, which reduces near-term balance sheet risk but also implies they see enough pipeline activity to keep M&A optionality alive.

The market may be underestimating how quickly the Huel-style acquisition can change the growth/margin mix over 12-24 months. If completion drags into 2026, investors may focus on the current slowdown in Specialty Nutrition and over-discount the value of the portfolio shift; if approval comes through, the incremental exposure to premium, higher-growth nutrition could re-rate the multiple. The contrarian risk is that recurring one-offs in EMEA and weather-related disruptions in Asia create the appearance of resilience when the underlying organic run-rate is actually closer to the low end of guidance.

For now, this is more of a quality-stability name than a catalyst-rich long: upside comes from execution and mix, downside comes from continued regional shocks or a stronger euro. The stock should likely trade on guidance credibility and margin durability over the next 1-2 quarters, not on the quarter itself.

Key Decisions for Investors

• Long DANO on pullbacks over the next 1-2 weeks; target a 3-5% drift higher if the market re-focuses on guidance credibility, with a stop if EMEA weakness broadens into the next print.
• Pair trade: long DANO / short a more FX-sensitive European consumer staple over the next quarter to isolate operational execution from translation risk; this works best if the euro stays firm and Asia momentum persists.
• Sell downside via cash-secured puts or put spreads 3-6 months out: the thesis is that current issues are transitory, so implied volatility should overstate fundamental downside unless the recall becomes systemic.
• Avoid chasing upside ahead of regulatory headlines on Huel/Argentina; add only after approval clarity, since deal completion is the cleaner catalyst for a 12-24 month re-rate.